---
document_datetime: 2023-09-21 17:16:52
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/steps-after-cutoff/agenerase-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
document_name: agenerase-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
version: success
processing_time: 2.1817851
conversion_datetime: 2025-12-28 01:11:02.983777
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## STEPS TAKEN AFTER GRANTING THE MARKETING AUTHORIZATION

For procedures finalised after 1 September 2004 please refer to module 8B.

Subsequent post Marketing Authorisation applications agreed upon are summarised in the table below:

| Scope                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Application number   | Type of modification 1   | Notification/ Opinion issued on 2   | Commission Decision Issued/amen ded on   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|--------------------------|-------------------------------------|------------------------------------------|
| Changes to comply with supplements to pharmacopoeias                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | I/0001               | I                        | 30.03.01                            | -                                        |
| Update of Summary of Product Characteristics (SPC) and Package Leaflet (PL): New interaction statements with Hypericum perforatum (St JohnÂ´s wort), methadone and combination oral contraceptive (OC).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | II/0002              | II                       | 27.06.01                            | authorised 24.10.01                      |
| Annual Re-assessment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | S/0003               | S                        | 21.02.02                            | 17.05.02                                 |
| _Change following modification(s) of the manufacturing authorisation(s)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | I/0004               | I                        | 30.05.02                            | 06.06.02                                 |
| Change following modification(s) of the manufacturing authorisation(s)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | I/0005               | I                        | 06.06.02                            | 10.07.02                                 |
| Change in the qualitative composition of immediate packaging material                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | I/006                | I                        | 12.05.03                            | 22.05.03                                 |
| Change in the batch size of finished product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | I/0008               | I                        | 25.04.02                            | 26.04.02                                 |
| Minor changes in manufacture of the medicinal product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | I/0009               | I                        | 25.04.02                            | 26.04.02                                 |
| no The MAH applied to update the SPC, section 4.4 (special warnings and special precautions for use) and section 4.5 (Interactions with other medicinal products and other forms of interaction). The proposed changes include an interaction between amprenavir and delavirdine, an interaction between amprenavir and efavirenz and the class labelling relating to co-medication of amprenavir with HMG-CoA reductase inhibitors. Corresponding PL changes (and minor revisions including an update of the list of local representatives) are proposed as well.                                                                                                                               | longer II/0010       | II                       | 25.05.02                            | 24.10.02                                 |
| product The MAH applied to update section 4.4 and section 4.8 of the SPC further to the CPMP request to implement the class-labelling for 'antiretroviral therapy (ART) and lipodystrophy' in the SPC. Corresponding amendments are proposed to the PL.                                                                                                                                                                                                                                                                                                                                                                                                                                          | II/12                | II                       | 19.03.03                            | 09.07.03                                 |
| Change in specification of the medicinal product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | I/0014               | I                        | 18.07.03                            | -                                        |
| Medicinal The variation concerns an update to sectionS 4.2 and 4.4 of the SPC as a class labelling on liver impairment and anti-HIV products adopted by the CPMPfor all anti-retroviral medicinal products on 25 April 2003. Relevant changes are equally proposed for the PL section 2. Lipodystrophy wording is also implemented in the PL Further proposed changes in SPC relate to contra-indication of co- administration with products with narrow therapeutic window that are substrates of CYP 3A4 and other forms of interaction in section 4.3, SPC interaction statement with Kaletra, and nevirapine in section 4.5 and re-arranged section 4.8, according to latest SPC guidelines. | II/0016              | II                       | 20.11.03                            | 29.01.04                                 |

<div style=\"page-break-after: always\"></div>

| The variation concerns an update to sections 4.1and 4.2, 4.3, 4.4 4.5, 4.8, 5.1 and 5.2 of the SPC with statements relating to the completion of specific obligation study PRO 300017 (a phase III randomised multicentre open-label study to evaluate the efficacy, safety and tolerance of Agenerase 600 mg BID in combination with ritonavir (100 mg BID) versus other PIs in HIV-infected PI- experienced adults over a 16 week period). Consequential changes are made to sections 1, 2 and 3 of the Package Leaflet (PL).   | II/0017   | II   | 20.11.03   | 29.01.04   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|------|------------|------------|
| Change in BR/QC testing - repl./add. of batch control/testing site                                                                                                                                                                                                                                                                                                                                                                                                                                                                | IA/0018   | IA   | 16.10.03   | -          |
| All specific obligations stated in Annex II.C of the CPMP opinion dated 23 January 2003 have been fulfilled. There are no remaining grounds for the Marketing Authorisation to remain under exceptional circumstances.                                                                                                                                                                                                                                                                                                            | S/0019    | S    | 17.12.03   | 10.03.04   |
| Change in shelf-life of finished product - as packaged for sale                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | IB/0020   | IB   | 10.02.04   | -          |
| Change in the name and/or address of a manufacturer of the finished product                                                                                                                                                                                                                                                                                                                                                                                                                                                       | IA/0021   | IA   | 24.05.04   | -          |
| To include the additional local representatives of the MAHfor all 10 new European Member States and to present the list according to the latest EMEA/QRD Template.                                                                                                                                                                                                                                                                                                                                                                | N/0022    | N    | 21.06.04   | -          |

## Medicinal product no longer authorised exceptional circumstances. Change in shelf-life of finished product - as packaged for sale Change in the name and/or address of a manufacturer of the finished product To include the additional local representatives of the MAH for all 10 new European Member States and to present the list according to the latest EMEA/QRD Template.